287 related articles for article (PubMed ID: 17300863)
1. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.
Motamed MR; Najimi N; Fereshtehnejad SM
Clin Neurol Neurosurg; 2007 May; 109(4):344-9. PubMed ID: 17300863
[TBL] [Abstract][Full Text] [Related]
2. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
3. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
[TBL] [Abstract][Full Text] [Related]
4. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
[TBL] [Abstract][Full Text] [Related]
5. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
Wu X; Dastidar P; Kuusisto H; Ukkonen M; Huhtala H; Elovaara I
Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
7. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
8. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
Trojano M; Paolicelli D; Zimatore GB; De Robertis F; Fuiani A; Di Monte E; Livrea P
Neurol Sci; 2005 Dec; 26 Suppl 4():S179-82. PubMed ID: 16388354
[TBL] [Abstract][Full Text] [Related]
9. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
11. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
12. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
Wu X; Kuusisto H; Dastidar P; Huhtala H; Nikkari ST; Ukkonen M; Höyhtyä M; Elovaara I
Acta Neurol Scand; 2007 Jul; 116(1):43-8. PubMed ID: 17587254
[TBL] [Abstract][Full Text] [Related]
14. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
[TBL] [Abstract][Full Text] [Related]
15. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
Kobelt G; Jönsson L; Miltenburger C; Jönsson B
Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
[TBL] [Abstract][Full Text] [Related]
17. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Fernández O; Guerrero M; Mayorga C; Muñoz L; Leán A; Luque G; Hervás M; Fernández V; Capdevila A; de Ramón E
J Neurol; 2002 Aug; 249(8):1058-62. PubMed ID: 12195454
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
20. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
Río J; Nos C; Tintoré M; Téllez N; Galán I; Pelayo R; Comabella M; Montalban X
Ann Neurol; 2006 Feb; 59(2):344-52. PubMed ID: 16437558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
